Horizon Pharma plc Completes Acquisition of Crealta Holdings LLC

DUBLIN, IRELAND -- (Marketwired) -- 01/14/16 -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has completed its acquisition of Crealta Holdings LLC for approximately $510 million in cash.

About Horizon Pharma plc Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and rheumatology business units. Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.

Contacts:
Investors:
John Thomas
Executive Vice President, Strategy and Investor Relations
[email protected]

Tina Ventura
Vice President, Investor Relations
[email protected]

U.S. Media:
Geoff Curtis
Senior Vice President, Corporate Communications
[email protected]

Ireland Media:
Ray Gordon
Gordon MRM
[email protected]

Source: Horizon Pharma plc

You May Also Be Interested In

• AIAI Holdings begins acquisition talks with founder-controlled firm
• JFrog to Host Investor and Financial Analyst Event at swampUP 2026
• NextNav and Tiami Networks Partner to Protect Against Unmanned Aircraft System Threats